Primary HIV Drug Resistance among Recently Infected Cases of HIV in North-West India by C. K. Chauhan, P. V. M. Lakshmi, V. Sagar, A. Sharma, S. K. Arora, R. Kumar

“…Injecting drug user (IDU) has showed resistance to either nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) or nonnucleotide reverse transcriptase inhibitors (NNRTI). …”
Get full text

Biodistribution of a Mitochondrial Metabolic Tracer, [18F]F-AraG, in Healthy Volunteers by Jelena Levi, Heying Duan, Shahriar Yaghoubi, Juliet Packiasamy, Lyna Huynh, Tina Lam, Faiq Shaikh, Deepak Behera, Hong Song, Joseph Blecha, Salma Jivan, Youngho Seo, Henry F. VanBrocklin

“…Purpose. [18F]F-AraG is a radiolabeled nucleoside analog that shows relative specificity for activated T cells. …”
Get full text

A Spike-Based mRNA Vaccine Encapsulated in Phospholipid 1,2-Dioleoyl-sn-Glycero-3-PhosphoEthanolamine Containing Lipid Nanoparticles Induced Potent B- and T-Cell Responses Associat... by Afshana Quadiri, Swayam Prakash, Latifa Zayou, Nisha Rajeswari Dhanushkodi, Amruth Chilukuri, Gemma Ryan, Kelly Wang, Hawa Vahed, Aziz A. Chentoufi, Lbachir BenMohamed

“…Background: Nucleoside-modified mRNA encapsulated in lipid nanoparticles (LNPs) have emerged as a promising vaccine strategy, especially for COVID-19. …”
Get full text

Reverse transcriptase inhibitors diminish systemic proinflammatory responses to bacterial pathogens by Karthik Hullahalli, Katherine G. Dailey, Ryan Acbay, Masataka Suzuki, George I. Balazs, Matthew K. Waldor

“…Furthermore, nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) completely prevent tissue damage and subsequent bacterial growth within necrotic lesions. …”
Get full text

Exploring using HBsAg to predict interferon treatment course to achieve clinical cure in chronic hepatitis B patients: a clinical study by Fei Yan, Fei Tang, Jing Chen, YiCheng Lin, XinYu Chen, Qin Du, WeiLi Yin, Jing Liang, Lei Liu, Fang Wang, BaiGuo Xu, Qing Ye, HuiLing Xiang

“…This research aimed to develop an efficient model for predicting interferon (IFN) treatment course.MethodsPatients with chronic hepatitis B, undergoing PEG-IFN α-2b monotherapy or combined with NAs (Nucleoside Analogs), were recruited from January 2018 to December 2023 at Tianjin Third Central Hospital. …”
Get full text

The protein structurome of Orthornavirae and its dark matter by Pascal Mutz, Antonio Pedro Camargo, Harutyun Sahakyan, Uri Neri, Anamarija Butkovic, Yuri I. Wolf, Mart Krupovic, Valerian V. Dolja, Eugene V. Koonin

“…In addition, we identified a case of exaptation of a cellular nucleoside monophosphate kinase as an RNA-binding protein in several virus families. …”
Get full text

Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experien... by Alex Durand Nka, Yagai Bouba, Wilfried Rooker Tsapi Lontsi, Davy-Hyacinte Gouissi Anguechia, Georges Teto, Aude christelle Ka’e, Ezechiel Ngoufack Jagni Semengue, Collins Ambe Chenwi, Désiré Takou, Lum Forgwei, Tatiana Anim-Keng Tekoh, Aurelie Minelle Kengni Ngueko, Bernadette Bomgning Fokou, Jeremiah Efakika Gabisa, Michel Carlos Tommo Tchouaket, Willy Leroi TognaPabo, Derrick Tambe Ayuk Ngwese, Jacky Njiki Bikoi, Daniele Armenia, Vittorio Colizzi, Marcel Yotebieng, Nicaise Ndembi, Maria-Mercedes Santoro, Francesca Ceccherini-Silberstein, Carlo-Federico Perno, Alexis Ndjolo, Joseph Fokam

“…The M184V mutation, known to reduce ISL’s viral susceptibility in vitro, could arise from prolonged exposure to nucleoside reverse transcriptase inhibitors (NRTI) (3TC). …”
Get full text

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation by Oana Hangiu, Oana Hangiu, Oana Hangiu, Rocío Navarro, Susana Frago, Laura Rubio-Pérez, Laura Rubio-Pérez, Laura Rubio-Pérez, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Laura Díez-Alonso, Laura Díez-Alonso, Laura Díez-Alonso, Marina Gómez-Rosel, Marina Gómez-Rosel, Marina Gómez-Rosel, Noelia Silva-Pilipich, Noelia Silva-Pilipich, Lucía Vanrell, Cristian Smerdou, Cristian Smerdou, Kenneth A. Howard, Laura Sanz, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Marta Compte

“…The mRNA encoding these bispecific antibodies contains an N1-methylpseudouridine modified nucleoside and regulatory sequences to ensure proper expression and stability. …”
Get full text

Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort by Valériane Leroy, Anandi Sheth, Julie Jesson, Jean Jacques Koffi, Antoine Jaquet, François Dabis, Didier Koumavi Ekouevi, Karen Malateste, Olivia Keiser, Lehila Bagnan, Simon Boni, Madeleine Amorissani Folquet, Mariam Sylla, Olivier Marcy, Raoul Moh, Gildas Boris Hedible, Sophie Desmonde, Joycelyn Dame, Agatha David, Madeleine Amorissani-Folquet, Sylvie N'Gbeche, Elom Takassi, François Tanoh Eboua, Kouadio Kouakou, Lehila Bagnan Tossa, Caroline Yonaba, Jocelyn Dame, Sylvie Marie N’Gbeche, Fatoumata Dicko Traore, Oliver Ezchechi, Rosemary Audu, Charlotte Bernard, Caroline Couturier, Marie Kerbie Plaisy, Elodie Rabourdin, Thierry Tiendrebeogo, Désiré Dahourou, Emile Sodinyessi, Jean-Claude Azani, Kadidja Diarra, Maika Bengali, Abdoulaye Cissé, Guy Gnepa, Eric Komena, Séverin Lenaud, Eulalie Kangah, Igho Ofotokun, Cecile Delille Lahiri, Noëlle Benzekri, Geoffrey Gottlieb

“…Adjusted on ART line and available viral load (VL) at baseline, females aged >10 years were less likely to initiate DTG compared with males of the same age (adjusted HR among 10–14 years: 0.62, 95% CI 0.54 to 0.72; among ≥15 years: 0.43, 95% CI 0.36 to 0.50), as were those with detectable VL (>50 copies/mL) compared with those in viral suppression (aHR 0.86, 95% CI 0.77 to 0.97) and those on PIs compared with those on non-nucleoside reverse-transcriptase inhibitors (aHR after 12 months of roll-out: 0.75, 95% CI 0.65 to 0.86).Conclusion Paediatric DTG uptake was incomplete and unequitable in west African settings: DTG use was least likely in children <5 years, females ≥10 years and those with detectable VL. …”
Get full text